Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ: GOSS) to Market Perform from Outperform, citing Merck & Co Inc's (NYSE: ...
DISCLAIMER
Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.
Categories
Best Stocks to buy now
Crypto
Dow Jones Today
Pre-IPO and Startups
Tech stocks
Utility Stocks
Data and Tools
Quote
Dow Jones Today
© 2023 Best Stocks